1. Home
  2. Press release
Jul 09, 2020 12:11 JST

Source: Eisai

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 09, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting. These data were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting and supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Eisai's and Merck's applications, another combination therapy was approved based on a randomized controlled trial that demonstrated overall survival. Consequently, the CRL stated that the applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for Study 116/KEYNOTE-524 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the LENVIMA plus KEYTRUDA combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the currently approved indications for LENVIMA or for KEYTRUDA.

Eisai and Merck are continuing to evaluate the LENVIMA plus KEYTRUDA combination across 13 different tumor types in 18 clinical trials including the LEAP (LEnvatinib And Pembrolizumab) clinical program.

For more information, visit https://www.eisai.com/news/2020/news202039.html.

Contact:
Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
  
Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211
Source: Eisai
Sectors: BioTech, Healthcare & Pharm

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
 
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
 
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
 
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
 
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
 
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
More Press release >>

Latest Press Release


Mitsubishi Motors to Launch All-New Eclipse Sportback EV in the United States and Canada
Jun 10, 2026 23:15 JST

Bosch Home Comfort Group and Hitachi Group agree to collaborate on Intelligent connectivity and diagnosis solutions for Commercial Air Conditioning based on "HMAX for Buildings"
Jun 10, 2026 22:47 JST

Hitachi and Google Cloud expand strategic alliance to accelerate real-world deployment of physical AI through FDE and advanced cybersecurity solutions
Jun 10, 2026 22:18 JST

Toyota to participate in the "1000 Miglia Gran Turismo Experience 2026," a special program of the historic Italian rally, the 1000 Miglia
Jun 10, 2026 21:39 JST

Mazda Advances Toward Commercialization of Onboard CO2 Capture System
Jun 09, 2026 00:03 JST

Collaboration Between OCTARVIA Programs and MiPoLin(R)
Jun 08, 2026 23:34 JST

Hitachi joins Anthropic's "Project Glasswing" an AI-powered security program
Jun 08, 2026 23:04 JST

Hitachi and Intel announce strategic collaboration to accelerate AI transformation across key industries
Jun 08, 2026 22:38 JST

Island States Ocean Summit Concludes Launch of the "OCEAN STATES INITIATIVE"
Jun 08, 2026 14:00 JST

Operations Started for the Nagaoka Methanation Demonstration Utilizing the CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates

Jun 04, 2026 23:49 JST

Fujitsu and Daiichi Life Group Launch Joint Research to Advance Asset Management with Quantum Technology
Jun 04, 2026 23:17 JST

"Making Children and Adults Smile:" Honda Launches the SMILE RIDER PROJECT
Jun 04, 2026 22:46 JST

GR Premiers GRMN Corolla
Jun 04, 2026 22:05 JST

Island States Ocean Summit Opens in Tokyo
Jun 04, 2026 12:00 JST

Mazda and Nippon Express Launch Demonstration Trial Using Biodiesel Fuel
Jun 04, 2026 00:26 JST

NEC Wins at the Newsweek AI Impact Awards 2026
Jun 04, 2026 00:09 JST

Mitsubishi Heavy Industries and Preferred Networks Form Business Alliance to Jointly Develop Japan-Made AI Technologies for Mission-Critical Applications
Jun 03, 2026 23:51 JST

JAL Engineering and Mitsubishi Heavy Industries Establish Joint Venture "Aero Breath" for Aircraft Aftermarket Business
Jun 03, 2026 23:27 JST

MHI Receives Waste Treatment Technology Verification Report from JESC for Its Biomass High-Efficiency Recovery and Recycling System AdBio
Jun 03, 2026 23:02 JST

DUNLOP and Fujitsu Reduce Tire Structural Analysis Time by Approximately 90% Using AI
Jun 03, 2026 22:31 JST
 More Latest Release >>